Bio-Techne (TECH) CEO exercises awards, 10.8K shares withheld
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reports that Chief Executive Officer Kim Kelderman had multiple equity award updates on 8/15/2026. Several performance restricted stock units and options were exercised or converted into common stock, and other performance-based awards were disposed of to the issuer or forfeited following Board actions on discretionary vesting. Kelderman acquired 21,470 shares of common stock through exercises, while 10,821 shares of common stock were delivered or withheld to cover exercise price or tax liability. Footnotes state the Board authorized discretionary vesting for specified tranches of performance RSUs and options, with remaining portions forfeited, and that Kelderman continues to hold multiple stock option grants and performance RSUs covering substantial numbers of underlying BIO-TECHNE common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,649 shares
Net Buy
20 txns
Insider
Kelderman Kim
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Restricted Stock Units F2, F3 | 554 | $0.00 | $0.00 |
| Disposition | Performance Restricted Stock Units F2, F3 | 8,319 | $0.00 | $0.00 |
| Disposition | Performance Stock Options (Right to Buy) F4 | 22,389 | $0.00 | $0.00 |
| Exercise | Performance Restricted Stock Units F2, F7 | 588 | $0.00 | $0.00 |
| Disposition | Performance Restricted Stock Units F2, F7 | 8,835 | $0.00 | $0.00 |
| Disposition | Performance Stock Options (Right to Buy) F8 | 24,324 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F2, F11 | 8,543 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F2, F14 | 11,785 | $0.00 | $0.00 |
| Exercise | Common Stock | 21,470 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 10,821 | $72.40 | $783K |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F6 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F9 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F10 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F12 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F13 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F15 | -- | -- | -- |
Holdings After Transaction:
Performance Restricted Stock Units — 121,969 shares (Direct);
Performance Stock Options (Right to Buy) — 3,113 shares (Direct);
Restricted Stock Units — 32,113 shares (Direct);
Common Stock — 82,762 shares (Direct);
Stock Option (Right to Buy) — 141,668 shares (Direct);
Stock Options (Right to Buy) — 307,975 shares (Direct)
Footnotes (15)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited.
- F4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,492 performance options. The remainder of the performance options were forfeited.
- F5. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F6. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F7. On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited.
- F8. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,621 performance options. The remainder of the performance options were forfeited.
- F9. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F10. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- F12. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F13. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F14. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F15. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Common shares acquired via exercise: 21,470 shares
Shares delivered/withheld for exercise price or tax: 10,821 shares
Performance RSUs discretionary vesting tranche 1: 554 units
+5 more
8 metrics
Common shares acquired via exercise
21,470 shares
Common Stock, code M transaction on 2026-08-15
Shares delivered/withheld for exercise price or tax
10,821 shares
Common Stock, code F at $72.40 per share on 2026-08-15
Performance RSUs discretionary vesting tranche 1
554 units
Board authorized discretionary vesting; remainder forfeited (footnote F3)
Performance RSUs discretionary vesting tranche 2
588 units
Board authorized discretionary vesting; remainder forfeited (footnote F7)
Performance options discretionary vesting 1
1,492 options
Board authorized discretionary vesting; remainder forfeited (footnote F4)
Performance options discretionary vesting 2
1,621 options
Board authorized discretionary vesting; remainder forfeited (footnote F8)
Option position at $66.97
115,724 underlying shares
Stock Option (Right to Buy), exercise price $66.97, expiring 2027-08-05
Option position at $53.60
90,441 underlying shares
Stock Options (Right to Buy), exercise price $53.60, expiring 2035-08-15
Key Terms
Performance Restricted Stock Units, Stock Options (Right to Buy, discretionary vesting, exercise price, +1 more
5 terms
Performance Restricted Stock Units financial
"Performance Restricted Stock Units were exercised, disposed, and remain as holdings"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Options (Right to Buy financial
"Stock Options (Right to Buy) with specified exercise prices and expirations"
discretionary vesting financial
"the Board of Directors authorized discretionary vesting for certain performance awards"
exercise price financial
"options with exercise prices such as $66.9700 and $53.6000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
forfeited financial
"the remainder of the performance options or RSUs were forfeited"
FAQ
What equity transactions did BIO-TECHNE (TECH) CEO Kim Kelderman report on 8/15/2026?
On 8/15/2026, CEO Kim Kelderman reported exercises of restricted stock units and performance RSUs, dispositions of other performance awards to the issuer, and one acquisition of 21,470 common shares through derivative exercises, alongside share withholdings for exercise price or tax obligations.
What happened to BIO-TECHNE (TECH) performance RSUs held by Kim Kelderman on 8/15/2026?
The Board authorized discretionary vesting for 554 and separately 588 performance RSUs, while the remainder of those performance RSUs were forfeited. Additional performance RSU tranches remain outstanding and may vest in future if performance goals are achieved.
What performance stock options of BIO-TECHNE (TECH) were affected by Board actions on 8/15/2026?
The Board authorized discretionary vesting for 1,492 and separately 1,621 performance stock options on 8/15/2026, and the remaining options in those awards were forfeited. Other option grants with various exercise prices and vesting schedules remain in place.
What stock option positions does BIO-TECHNE (TECH) CEO Kim Kelderman continue to hold?
Kelderman continues to hold multiple stock option grants, including options over 115,724 shares at an exercise price of $66.97 expiring 8/5/2027 and options over 90,441 shares at $53.60 expiring 8/15/2035, among other grants.
Were BIO-TECHNE (TECH) CEO Kim Kelderman’s Form 4 transactions under a Rule 10b5-1 plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirmative, and no footnote describes these transactions as executed under a Rule 10b5-1 trading plan, based on the provided data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
